Mission Bay Capital has backed a series B round for orphan diseases drug developer Glycomine, which also attracted Novo, Asahi Kasei Pharma and Chiesi.

US-based biotechnology developer Glycomine obtained $33m in a series B round on Wednesday backed by Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences (QB3). Pharmaceutical firm Novo led the round, which also featured pharmaceutical companies Asahi Kasei Pharma and Chiesi, the latter participating through corporate venturing subsidiary Chiesi Ventures. Investment…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.